Kevin Dunleavy
Kevin Dunleavy
Recovering sportswriter, now a reporter for @FiercePharmaSource
Fairfax, Virginia
CRITIC
img-contested
N/A
0 reviews
PUBLIC
img-contested
N/A
2 reviews

RECENT ARTICLES

Sort by:
No Rating
Former AstraZeneca exec charged with insider trading in Daiichi Sankyo's licensing deal

Former AstraZeneca exec charged with insider trading in Daiichi Sankyo's licensing deal

Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs. According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s global head of corporate affairs for oncology—has been charged with taking advantage of his advance knowledge of the 2019 deal to buy $20,000 worth of stock. Joublin became aware of AZ’s impending deal to acquire commercial rights to Daiichi Sankyo’s breast cancer drug Enhertu on March 6, 2019, the filing alleges; six...

May 31
Share
Save
Review
  • Total 1 items
  • 1
OUTLETS
fiercepharma.com

fiercepharma.com

CRITIC
img-contested
N/A
PUBLIC
img-contested
N/A